No results for ‘’
Zydus Lifesciences Ltd
₹1070.80
(0.34%)
Sun, 21 Jun 2026, 08:27 am
Health Technology
Pharmaceuticals: Major
24.5KZydus Lifesciences Price to Sales Ratio (P/S)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 27.83 | 18.02 | 12.42 | 12.26 | 22.30 | 22.78 | 23.85 | 23.23 | 26.15 | 31.01 | 16.78 | 30.51 | 21.82 | 19.19 | 23.24 | 21.15 | 19.76 | 25.47 | 26.36 | 19.69 |
| Price to book ratio | 6.07 | 4.87 | 3.01 | 3.01 | 6.92 | 7.46 | 6.05 | 5.16 | 6.11 | 8.40 | 5.69 | 6.52 | 4.43 | 3.42 | 2.64 | 3.47 | 2.10 | 2.84 | 5.10 | 3.72 |
| Price to sales ratio | 2.94 | 2.36 | 1.41 | 1.30 | 3.15 | 3.63 | 3.06 | 2.47 | 2.98 | 4.19 | 3.51 | 4.89 | 3.30 | 2.74 | 1.95 | 3.16 | 2.37 | 2.93 | 5.28 | 3.90 |
| Price to cash flow ratio | 38.15 | 16.71 | 17.24 | 16.96 | 17.80 | 25.84 | 41.65 | 33.08 | 27.25 | 36.78 | 16.97 | 34.54 | 44.84 | 12.42 | 10.32 | 14.29 | 17.40 | 18.91 | 30.98 | 12.97 |
| Enterprise value | 4643Cr | 4587Cr | 3969Cr | 4772Cr | 12143Cr | 17048Cr | 17463Cr | 17531Cr | 23253Cr | 37641Cr | 34188Cr | 49148Cr | 42630Cr | 43796Cr | 35446Cr | 50589Cr | 38513Cr | 52094Cr | 103000Cr | 86933Cr |
| Enterprise value to EBITDA ratio | 19.09 | 14.97 | 10.03 | 8.61 | 16.22 | 19.29 | 18.76 | 18.75 | 26.63 | 23.30 | 14.89 | 26.79 | 15.51 | 15.64 | 13.52 | 15.34 | 12.27 | 15.26 | 20.38 | 13.34 |
| Debt to equity ratio | 0.64 | 0.53 | 0.79 | 1.04 | 0.67 | 0.49 | 0.89 | 0.99 | 0.79 | 0.63 | 0.43 | 0.75 | 0.62 | 0.76 | 0.77 | 0.35 | 0.25 | 0.07 | 0.04 | 0.13 |
| Return on equity % | 23.59 | 29.89 | 26.73 | 26.39 | 35.28 | 37.42 | 27.51 | 23.69 | 25.18 | 29.92 | 38.92 | 23.55 | 22.85 | 19.33 | 11.33 | 18.84 | 14.95 | 11.39 | 20.55 | 20.67 |
Zydus Lifesciences Ltd Price to Sales Ratio
The Zydus Lifesciences Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Zydus Lifesciences Ltd's valuation, profitability, and overall financial performance. Tracking the Zydus Lifesciences Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE, BSE: 532321) is currently trading at ₹1070.80, with a market capitalization of ₹107757.6Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Zydus Lifesciences Ltd Price to Sales Ratio is essential for fundamental analysis.
Zydus Lifesciences Ltd Price to Sales Ratio Current Value
The current Zydus Lifesciences Ltd Price to Sales Ratio stands at 3.90.
The Zydus Lifesciences Ltd Price to Sales Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Zydus Lifesciences Ltd Price to Sales Ratio Historical Trend
The Zydus Lifesciences Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 3.90
- 2023: 5.28
- 2022: 2.93
- 2021: 2.37
- 2020: 3.16
The decline in Zydus Lifesciences Ltd Price to Sales Ratio indicates improving financial efficiency or better earnings growth.
What Zydus Lifesciences Ltd Price to Sales Ratio Indicates for Investors
The Zydus Lifesciences Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Zydus Lifesciences Ltd Price to Sales Ratio Analysis Summary
The Zydus Lifesciences Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Zydus Lifesciences Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Zydus Lifesciences Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.